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Abstract
Background: Hepatitis B and hepatitis C viruses are the most common types of viruses that
infect the liver. Infection by these viruses during pregnancy have high rate of vertical
transmission and have adverse effect on both the mother and child. Infection at the prenatal age
and infancy usually leads to a chronic carrier status. Epidemiological data for these viruses are
important to take appropriate preventive measures.
Objective: The aim of this study was to determine the sero-prevalence and associated risk
factors of hepatitis B virus and hepatitis C virus infections among pregnant women at Dessie
referral hospital.
Methods: A cross sectional study was conducted from March to May, 2014 at Dessie referral
hospital antenatal care clinic. A pre-tested structured questionnaire was used to collect data on
socio-demographic and other variables. Five milliliter of venous blood was collected from each
study subject. Serum was separated and tested for hepatitis B surface antigen (HBsAg) and anti-
HCV antibody using rapid test kits. Data was entered and analyzed using SPSS version 16.0
computer software. Logistic regression analysis was employed to examine the possible risk
factors of hepatitis B virus and hepatitis C virus infections. P-value < 0.05 was considered as
statistically significant.
Results: A total of 385 pregnant women were involved in this study and their mean age was
28.16 ± 5.37 years. The overall prevalence of HBsAg and anti- hepatitis C virus antibody was
4.9% and 0.8% respectively. High proportion of HBsAg positivity was found among these had
no formal education (47.4%) and widowed (22.2%). History of multiple sexual practices, nose
piercing and history of abortion had statistically significant association with HBsAg sero-
positivity (p < 0.05). All of the anti- hepatitis C virus antibody positive pregnant women had
history of ear piercing, history of abortion, and positive for human immunodeficiency virus.
Conclusion: This study has shown that intermediate and low prevalence of hepatitis B virus and
hepatitis C virus infection among pregnant women respectively. Increasing awareness of
transmission of HBV through multiple sexual practice and nose piercing is needed.  Routine
screening of pregnant women for hepatitis B virus and hepatitis C virus is also recommended.
Key Words: Hepatitis B virus, Hepatitis C virus, pregnant women, Dessie Referral Hospital
11. Introduction
1.1. Background and Statement of the Problem
Viral hepatitis is an inflammation of the liver due to viral infection. It is a global public health
problem affecting millions of people every year. Five different types of hepatitis viruses (A – E)
are responsible for viral hepatitis (1, 2). Of these five viruses, hepatitis B virus (HBV) and
hepatitis C virus (HCV) are the most common types of viruses that infect the liver. These viruses
are members of two different viral families, but both display a strong hepatotropism and can
cause acute or chronic infections. Those chronically infected with HBV and HCV are at risk of
serious illness and death from cirrhosis and hepatocellular carcinoma (HCC) (3).
Hepatitis B virus is an enveloped deoxyribonucleic acid (DNA) virus belonging to the family
Hepadnaviridae. The viral genome consists of partially double-stranded DNA with a short,
single stranded piece. It comprises 3200 nucleotides, making it the smallest DNA virus known
(3, 4). The virus is transmitted through exposure to infectious blood, semen, and other body
fluids (3). Hepatitis B virus can also be transmitted from infected mothers to infants or from
family members to infants in early childhood (5). Transmission may also occur through unsafe
sexual intercourse, transfusions of HBV-infected blood and blood products, contaminated
injections during medical procedures, and sharing of needles and syringes among injecting drug
users (6).
World Health Organization (WHO) estimates that about two billion people have been infected
with HBV worldwide and more than 240 million people are chronically infected with the virus.
About 500, 000 – 700, 000 people die annually as a result of HBV infection (2). During HBV
infection the risk of chronicity varies greatly with the age at which the infection is acquired. For
neonates and children younger than one year who acquire the infection, the risk of the infection
becoming chronic is 90%. For children aged 1–5 years, the risk is about 30%, and for children
older than 5 years and for adults, the risk decreases to around 2% (6).
Hepatitis C virus is a small single-stranded ribonucleic acid (RNA) virus that belongs to the
Flaviviridae family (3). This virus is mostly transmitted through exposure to infectious blood.
This may happen through transfusions of HCV-infected blood and blood products, contaminated
injections during medical procedures, and sharing of needles and syringes among injecting drug
users (7). Vertical transmission from infected mother to fetus or transmissions through unsafe
2sexual contact are other possible modes of transmission of the virus (5). Infection with HCV is a
major cause of chronic hepatitis around the world and about 2 – 3% of the world populations are
living with HCV infection. More than 350, 000 deaths are attributed to HCV infection each year,
most of which are caused by liver cirrhosis and HCC (7).
Hepatitis B virus and HCV are different in carriage rate, natural history and mother to fetus
transmission rate (8). For instance about 75 - 85% of patients with HCV will develop chronic
infection and about 10 - 15% of patients with HCV develop liver cirrhosis (9).  But about 10% of
adult patients with HBV will develop chronic infection and about 15 – 40% of those chronically
infected patients develop liver cirrhosis and HCC (10). The rate of chronic infection is affected
by many factors such as age at time of infection, gender, ethnicity, and the development of
jaundice during the acute infection (9). The main reason for the difference in the rate of chronic
infection is that HCV evades the immune system more easily than HBV; because HCV mutates
more rapidly (8). Hepatitis C virus spreads throughout the immune system by mutating certain
parts of its genome; making cluster of differentiation (CD8+) T- cells unable to find them and
destroy them. But undergoing this process also disables some of its ability to replicate.
Pregnancy causes a woman’s immune system to withhold T-cells in order to prevent any attack
on the growing fetus. This in turn, allows the virus to replicate without opposition by T-cells. In
this case, escape mutations were lost, meaning that the virus didn’t need to mutate. This
condition is responsible for the developments of virus strains that replicates faster and easily
transfer to the fetus (11, 12).
Hepatitis B virus and HCV are also different in their vertical transmission rate. The risk of
vertical transmission of HBV depends on the time at which the pregnant woman acquired
infection, and on her statuses of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen
(HBeAg). The risk of perinatal HBV infection in an infant with an HBsAg positive mother is less
than 10% if the mother’s HBeAg status is negative. But it is about 70 – 90% if the mother’s
HBeAg status is positive (5, 13). Similarly the risk of vertical transmission of HCV depends on
positivity of the mother for HCV RNA and if the mother is positive for HCV RNA, the rate of
vertical transmission is about 4.3% if she is not co-infected with human immunodeficiency virus
(HIV). If the mother is co-infected with HIV, the rate of vertical transmission increases up to
19.4% (5). If infected at birth, an infant has approximately a 90% chance of becoming a chronic
3HBV carrier. Although rates of new infection and acute disease are highest among adults, the
rate of progression from acute to chronic HBV infection is less for adult acquired infection (13).
Viral hepatitis during pregnancy is associated with high risk of maternal complications including
premature contractions, preterm delivery, placental separation, premature rupture of membranes,
vaginal bleeding, gestational diabetes mellitus and mortality (14, 15). Carriers of HBsAg have
increased risk of gestational diabetes mellitus, antepartum haemorrhage, and threatened preterm
labour (16). This may be related to the chronic inflammatory state in these subjects. Hepatitis B
virus and HCV during pregnancy have a high vertical transmission rate, causing perinatal
mortality, congenital malformations and low birth weight (17). Neonatal hepatitis can lead to
chronic virus carriage, which in turn may lead to liver cirrhosis and HCC in young adults (5).
Infection in the neonatal period is associated with failure to produce antibody to HbsAg,
allowing chronic carriage to occur in nearly 100% which is a risk to develop HCC (13).
The prevalence of HBV infection varies greatly in different regions of the world and it is highly
endemic in areas such as sub-Saharan Africa, Asia, the Pacific Basin, parts of the Middle East
and the Amazon Basin (18). The global burden of HBV infection in pregnant women is not
exactly known but the prevalence of infection among women of child-bearing age group is about
8.16% (19).The global  prevalence of HCV infection in pregnant women ranges from 0.15 -
2.4% in developed countries and 1 - 8% in developing countries (20). The mother to child
transmission of these viruses may occur before birth through transplacental transmission, during
delivery, or postnatal transmission during care or through breast milk (13, 20).
Although different studies on the prevalence of HBV and HCV have been conducted in different
parts of Ethiopia, most of them focused on investigating the prevalence of HBV and HCV among
blood donors (21, 22), HIV infected individuals (23), health care workers (24) and medical waste
handlers (25). Only very few studies were conducted in Jimma town (26), Gondar town (27),
and Debre-Tabor town (28) to determine the prevalence of HBsAg among pregnant women. To
our knowledge, only one study was conducted in Gondar town to determine the prevalence of
anti-HCV antibody among pregnant women (27). We believe that, there is very limited or no
data about the magnitude of HBV and HCV prevalence among pregnant women in Dessie town
and the adjacent administrative areas. Therefore, the aim of this study was to provide baseline
information on the magnitude of HBV and HCV infections among pregnant women together
4with the associated risk factors in Dessie town. We believe that this study provided relevant and
recent information valuable for treatment, prevention and control of HBV and HCV infection.
1.2. Literature Review
The magnitude of HBV and HCV infections among pregnant women was reported at different
settings with difference in occurrence. For example, a study conducted in India designed to
investigate the sero-prevalence of HBsAg in pregnant women and possible risk factors for
perinatal HBV transmission showed a prevalence of 0.9% (29). In the same country the
prevalence of anti-HCV antibody was 1.03% (30).
In Italy, the prevalence of chronic HCV infection was evaluated in 15,250 cohorts of pregnant
women. The result of this study showed 2.4% of women were positive for anti-HCV antibody
and 72% of those anti-HCV antibody positive women were positive for HCV RNA. In this study
intravenous drug abuse, history of blood transfusion, accidental blood contact in health care
workers and sexual intercourse with HCV positive partner were the major risk factors (31).
A cross sectional study conducted in Pakistan; aimed to assess the frequency of anti – HCV
antibody, HBsAg and risk factors in pregnant women in 2006 – 2007 revealed a prevalence of
7% and 4.6% for anti - HCV antibody and HBsAg respectively. Previous history of surgery,
multiple injection therapy and blood transfusion were observed as risk factors among anti – HCV
antibody and HBsAg positive pregnant women (32).
In 2008, a cross sectional study conducted in Iran showed that the prevalence of HBsAg was
0.7% and that of anti-HCV antibody was 0.2% among pregnant women (33).  Another cross-
sectional study conducted on pregnant women in Sana’a, Yemen by the year 2011 reported a
10.8% and 8.5% prevalence of HBsAg and anti-HCV antibody respectively. Low parity and
educational status below secondary level were significantly associated with anti- HCV sero-
positivity (34).
In Saudi Arabia, the prevalence of HBV infection among pregnant women in 2011 was reported
4.1%. This study also indicated that the prevalence of HBV increases in old age. History of
hospitalization and jaundices were the main risk factors associated with sero-prevalence of HBV
infection (35).
5Zeba etal’s report by the year 2009 in Burkina Faso determine the prevalence of HCV and co-
infection with HIV among pregnant women and found an overall prevalence of HCV infection of
2.14%. The prevalence of HCV was 1.75% and 2.38% for HIV - negative and HIV - positive
pregnant women respectively. This study revealed that history of blood transfusion and genital
excision were risk factors for HCV positivity in pregnant women (36).
A study report in Yaounde, Cameroon, by the year 2012 showed a prevalence of 7.7% for
HBsAg among pregnant women. History of contact with known HBsAg positive individual was
independent predictor of sero-prevalence of HBV infection (37).
In Mali, the sero-prevalence of HBsAg among pregnant women was reported 8% by the year
2009. This study also showed that 0.38% of HBsAg positive women were co-infected with HIV.
Age, parity, genital excision, birth weight of baby and HIV status were not associated with HBV
infection (38).
Different studies conducted in different states of Nigeria showed that the prevalence of HBV
infection among pregnant women ranges from 6.67 – 9.5% (39 - 43). A study conducted in
Anambra State, Nigeria in 2003 revealed that 8.6% of the women were sero-positive for HIV,
9.3% for HBsAg and 0.7% HIV - HBV co-infection. The prevalence rates of the infections were
inversely associated with increase in educational status (39). Similarly in Nasarawa State,
Nigeria in 2009, a prevalence of 6.67% HBsAg were reported (40). Furthermore, in 2011 another
case control study was conducted in Kano state, Northwest Nigeria and reported prevalence of
HBsAg among pregnant and non pregnant women were 7.9 and 7.6%, respectively. The risk
factors associated with HBV infection were blood transfusion, ear piercing, tattooing, and
abortion among pregnant women (41).
In Nigeria other studies to determine the prevalence of both HBV and HCV in pregnant women
were carried out. A hospital based cross sectional study conducted in 2009 in Abuja showed
prevalence of 9.5% and 0.5% of HBV and HCV respectively (42). In another cross sectional
study conducted in Benin City, Nigeria in 2012 the prevalence of HBV and HCV infections were
2.2% and 0.8% respectively (43).
The prevalence of HCV infection among pregnant women was reported 8.6% for HCV antibody
and 6.8% for HCV-RNA in Egypt in 2008. In this study old age, history of blood transfusion,
HCV infection of the husband or other household members was significantly associated with
6positivity of HCV. The same study showed that out of 53 infants tested at first month, 81% were
positive for HCV antibody, but only 13% were positive for HCV-RNA. After 6 months, only
3.8% remained positive for HCV RNA (44).In the same country the prevalence of HBsAg was
1.75% in a study conducted in 2011. Family history of HBV infection, previous intravenous
injections, hospital admission, and surgeries were the risk factors for acquiring HBV infection
(45).
Sero-prevalence study on HBV and HCV infection among pregnant women in Sudan showed
that 5.6% of women were positive for HBsAg and 0.6% of women were positive for anti – HCV
antibody. Expected risk factors such as age, parity, gestational age, residence, history of blood
transfusion, dental manipulations, tattooing and circumcision did not show association with
HBsAg sero-positivity (46).
In Ethiopia, only very few studies are conducted among pregnant women to determine HBV and
HCV prevalence and associated risk factors. A cross sectional study conducted in 2003 in Jimma
University Specialized Hospital and its four training health centers (Jimma, Asendabo, Agaro
and Shebe health centers) showed that the overall prevalence of HBsAg was 3.7%. Higher
prevalence of HBsAg (7.3%) was reported among pregnant women who have history of
abortion.  Even though the overall analysis showed no association between history of caesarian
section, dental procedure and tattooing, these risk factors were significant predictors of HBV
infection among pregnant women living in Jimma town (26).
Another cross sectional study conducted in 2006 to determine the sero-prevalence of HIV, HBV,
HCV and syphilitic infections among antenatal care clinic (ANC) attendees in Gondar town
found that the prevalence of HBV and HCV were 7.3% and 1.3% respectively (27). In 2004,
5.3% sero-prevalence of HBV infection among pregnant women attending ANC at Debre-Tabor
hospital was also reported (28).
71.3. Significance of the Study
Viral hepatitis remains a major source of morbidity and mortality throughout the world. The
occurrence of viral hepatitis during pregnancy is associated with high risk of maternal
complications. Additionally, HBV and HCV infected pregnant women are at risk of infecting
their babies through vertical transmission. Infection at fetal life and early age predisposes an
increased chance of becoming chronic virus carrier. Epidemiological data is essential to estimate
the burden and distribution of HBV and HCV among pregnant women. However, there are no
published data that showed the magnitude of HBV and HCV infection among pregnant women
in Dessie town.  Therefore, this study provides baseline and important information about the
prevalence of HBV and HCV prevalence among pregnant women which will certainly be
valuable for program mangers and health planners so as to initiate the relevant prevention and
control mechanisms for these viruses.
This study also provides information about risk factors for acquiring HBV and HCV infection
among pregnant women and it can be used as a base line data for further study on the area.
Therefore, the aims of this study were to assess the sero-prevalence of HBV and HCV infection
and also to determine the possible associated risk factors among pregnant women in Dessie
town, Northeast Ethiopia.
82. Objectives
2.1. General Objective
 The aim of this study was to assess the sero-prevalence and associated risk factors of HBV
and HCV infections among pregnant women at Dessie referral hospital.
2.2. Specific Objectives
 To determine the sero-prevalence of HBsAg among pregnant women at Dessie referral
hospital.
 To determine the sero-prevalence of anti- HCV antibody among pregnant women at
Dessie referral hospital.
 To identify the possible risk factors of HBV and HCV infections in pregnant women at
Dessie referral hospital.
93. Materials and Methods
3.1. Study Area
The study was conducted at Dessie referral hospital. Dessie referral hospital is found in Dessie
town. Dessie town is located in the Northeast part of Ethiopia in the South Wollo administrative
zone of the Amhara Region, which is 401 km away from the capital city, Addis Ababa.
According to the Central Statistics Agency 2007 report, Dessie has an estimated total population
of 151, 094. Dessie referral hospital was established in 1962 and has 17 departments with 300
beds. This referral hospital provides services to the population in the surrounding area of the
town and the adjacent regions. The antenatal clinic of the hospital serves about 3000 pregnant
women per year. The services delivered by the clinic includes assessment of pre-existing health
conditions (screening for anemia, syphilis, HIV), vaccination, nutrition counseling, micronutrient
supplementation and early detection of pregnancy related complications.
3.2. Study Design and Period
A cross sectional study was conducted from March 1 to May 30, 2014.
3.3. Population
3.3.1. Source Population
The source population was all pregnant women who have access to attend antenatal follow up at
Dessie referral hospital.
3.3.2. Study Population
The study population was all pregnant women who attend antenatal follow up at ANC of Dessie
referral hospital during the study period.
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3.4. Variables
3.4.1. Dependent Variables
 Sero-prevalence of HBV and HCV
3.4.2. Independent Variables
 Age
 Residence
 Marital status
 Educational status
 Occupation
 History of blood transfusion
 History of surgical procedure
 Ear piercing
 Nose piercing
 History of multiple sexual practice
 History of abortion
 Home delivery by traditional birth attendants
 Parity
 Gravidity
 HIV status
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3.5. Sample Size and Sampling Technique
3.5.1. Sample Size Determination
The sample size was determined using a single population proportion formula.
n = z
2 p (1-p)/ w2
= 3.8416 x 0.5 x0.5
0.0025
n = 385
Where:
n – The minimum sample size.
Z – Standard normal distribution value at the 95% CI, which is 1.96.
P – The proportion of sero-positive pregnant women, since there was no previous study in the
area we take it as 50%.
W – The margin of error, taken as 5%.
3.5.2. Sampling Technique
Systematic random sampling method was used to select the study participants among ANC
attendants. On average, about 12 pregnant women per day were expected to visit ANC at Dessie
referral hospital and there are 22 working days in a month. Considering three months study
period, 792 pregnant women were expected to visit the ANC during the study period. Therefore,
to get 385 sample size, the sampling interval was two. Of the first two subjects, one woman was
randomly selected by lottery method, and then every 2nd woman was selected to participate in the
study.
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3.6. Data Collection
3.6.1. Socio Demographic and Clinical Data
After written consent obtained from the study subjects, information concerning socio-
demographic and possible risk factors were collected through face to face interview using a
questionnaire. Nurses working at Dessie referral hospital ANC interviewed the study subjects
using structured questionnaire on socio-demographic and possible risk factors.
3.6.2. Blood Specimen Collection and Processing
Blood specimen was collected by trained laboratory technologist from each study subject. Five
milliliter (5ml) of venous blood was collected with plain tube by strictly following standard
operational procedures. Then the sample tube was labeled with the subject’s code number and
the blood specimen was allowed to clot at room temperature and serum was separated by
centrifugation at 5000 revolution per minute (rpm) for 10 minutes. All collected serum
specimens were tested for HBsAg and anti-HCV antibody using rapid diagnostic test kits
according to the manufacturer’s guidelines. Similarly, serum specimens were tested for HIV
using rapid test kits based on the current national HIV rapid test algorism of Ethiopia (Annex
VII).
3.6.3. Quality Control
Before using the prepared questionnaire for collection of information, it was checked for its
completeness and validity to get a reliable and clear data. The questionnaire was originally
developed in English and translated to Amharic (local language), then retranslated to English to
ensure consistency. To assure the quality of the data, the questionnaire was pretested before the
actual work and training were given to data collectors. The pre – test was conducted among
pregnant women attending gynecology department of Dessie referral hospital.
After collecting the data, the data were checked for completeness. Positive and negative control
samples within the test kits were run to assess the performance of the test kits.  Known positive
and negative serum samples for HBsAg and anti-HCV antibody confirmed by enzyme linked
immunosorbent assay (ELISA) technique was obtained from blood donation center of the
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Ethiopian Red Cross Association, Dessie branch. This known serum sample was analyzed before
the actual investigation as external quality control of the test kits.
3.7. Data Analysis and Interpretation
After completion of data collection, the data were checked for its completeness. Data were
entered and analyzed using Statistical Package for Social Sciences (SPSS) version 16.0.
Descriptive statistics was performed. Association between possible risk factors and sero-
positivity of HBV or HCV infection was determined using bivariate and multivariate logistic
regression analysis. Odds ratio was used as a measure of strength of association. The 95%
confidence interval and P – value less than 0.05 was taken as statistically significant.
3.8. Ethical Consideration
The study was conducted after getting institutional ethical clearance from Research and Ethical
Review Committee of the School of Biomedical and Laboratory Sciences, College of Medicine
and Health Sciences, University of Gondar. Official permission from Dessie referral hospital was
also obtained. The study subjects were informed about the study process, its purpose and their
right to refuse from the study. Refusal from the study will not affect the benefits gained from the
clinic. Written informed consent was obtained from each volunteer. Confidentiality were kept for
all the data gained in the process by anonymous data collection and restricting access of people
other than data collectors to the data. Pregnant women who found positive for HBsAg and/or
anti-HCV antibody were linked to ANC physicians for monitoring and further management.
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4. Results
4.1. Socio-demographic Characteristics
A total of 385 pregnant women were included in the study. The mean age of the study subjects
were 28.2 years with a standard deviation of ± 5.37 years. Majority of the study subjects (64.7%)
were in the age group greater than 30 years. The majority of the study subjects (83.6%) were
urban dwellers. Three hundred and fifty three (91.7%) of the study subjects were married and
65.5% attend secondary school and above. Gravidity and parity status showed that about 62.1%
were pregnant for more than once (multigravidae) and 53.8% have one or more previous delivery
(Table 1).
Table 1: Socio-demographic characteristics of pregnant women attending Dessie referral hospital
ANC, Northeast Ethiopia, 2014
Variable N %
Age (Years) 18 - 30 249 64.7
31 - 40 136 35.3
Residence Urban 322 83.6
Rural 63 16.4
Marital Status Single 16 4.2
Married 353 91.7
Widowed 9 2.3
Divorced 7 1.8
Educational Status No formal education 52 13.5
Primary school 81 21
Secondary school and Above 252 65.5
Occupation Employed 135 35.1
Housewife 201 52.2
Daily Laborers 17 4.4
Others 32 8.3
Gravidity Primigravida 144 37.4
Multigravida 241 62.6
Parity Nullipara 178 46.2
Multipara 207 53.8
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4.2. Sero-prevalence of HBV and HCV Infections
Among the 385 pregnant women screened, the sero-prevalence of HBsAg and ant-HCV antibody
were 19 (4.9%) and 3 (0.8%) respectively. The highest prevalence of HBsAg 5.9% (8/136) was
observed among the age group of greater than 30 years old. Relatively higher prevalence of
HBsAg 5.6% (18/ 322) was observed among urban dweller pregnant women. The highest
prevalence of HBsAg was observed in widowed women with a prevalence rate of 22.2% (2/9)
followed by singles 18.8% (3/16). An inverse relationship between the educational status of the
women and the sero-prevalence of HBsAg was observed. The prevalence of HBV infection was
found higher (25%) among pregnant women that had no formal education but the prevalence was
relatively lower among pregnant women that had educational level of secondary school and
above. Moreover, the prevalence of HBV infection was higher, 29.4% (5/17) among pregnant
women whom are daily laborers by occupation (Table 2).
The current study also determined the prevalence of HBV infection among HIV positive and
HIV negative pregnant women. Accordingly, fifty three pregnant women (13.8%) were positive
for HIV. Of these 53 HIV positive pregnant women, 22.6% (12/53) were co-infected by HBV. In
the current study there was no HBV and HCV co-infection.
The overall sero-prevalence of HCV was 0.8% (3/385). All the three pregnant women infected
by HCV were also co-infected by HIV (Table 2). Regarding gravidity status, all of the three anti-
HCV antibody positive pregnant women were pregnant for two and more times. In relation to
parity about 66.7% (2/3) anti-HCV antibody positive study subjects have two and above previous
delivery.
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4.3. Exposure to Risk Factors for HBV and HCV Infections
In this study, exposure to different risk factors for HBsAg and anti-HCV antibody positivity and
distribution of HBsAg and anti-HCV antibody was assessed. It was found that 8.6% of the
pregnant women had nose piercing, 74.5% ear piercing, 23.6% history of having multiple sexual
partners, 14.3% history of abortion, and 10.6% history of home delivery by traditional birth
attendants, 1% history of blood transfusion, 3.1% history of surgical procedures. HIV co-
infection was also considered as possible risk factor for Both HBV and HCV infection.
Accordingly, 13.8% of the pregnant women were also positive for HIV.
Among pregnant women that had a history of abortion, 23.6% (13/55) were positive for HBsAg
and the history of abortion was significantly associated with infection caused by the HBV (COR
16.7; 95% CI 6 – 46, P < 0.001). Fifteen of the 91 pregnant women with history of multiple
sexual practice, 15 women were positive for HBsAg (Table 2).
In order to investigate the association of socio-demographic variables and other factors with
HBsAg positivity, both bivariate and multivariate logistic regression analysis were done.
Bivariate logistic regression analysis showed that history of nose piercing (COR 9.9; 95% CI 3.6
– 26.9, P < 0.001) and history of having multiple sexual partners (COR 14.3; 95% CI 4.6 – 44.4,
P < 0.001) were significantly associated with HBV infection. Similarly, pregnant women that
had history of home delivery by traditional birth attendants (COR 5.7; 95% CI 2.1 – 15.4, P =
0.001) and HIV co-infection (COR 13.6; 95% CI 5 – 36.5, P < 0.001) had a higher risk for sero-
prevalence of HBV (Table 2). On the other hand, there was no statistically significant association
between age, residence, marital status, occupational status, ear piercing, history of surgical
procedures, history of blood transfusion and parity status with that of HBV infection among
pregnant women.
Multivariate logistic regression analysis showed that not having formal education, nose piercing,
history of multiple sexual practices and history of abortion were retained as determinant factors
for HBV infection (P < 0.05). Nevertheless, there was no statistically significant association
between gravidity status, home delivery by the help of traditional birth attendants and HIV status
with that of HBV infection (Table 2).
Educational status was also found determinant factor for HBV infection in the multivariate
model and pregnant women without formal education had a higher risk of acquiring HBV
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infection (COR 31.6; 95% CI 4.5 – 225, P = 0.001) than pregnant women that had formal
education (Table 2). Pregnant women having history of multiple sexual practices were 13 times
(AOR 13.5; 95% CI 2.3 – 78, P = 0.004) more likely of being infected by HBV than pregnant
women who had no history of multiple sexual practices. Likewise pregnant women that had
history of abortion were at a higher risk of being infected by HBV (AOR 9.1; 95% CI 1.9 – 44, P
= 0.005) than pregnant women with no history of abortion.
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Table 2: Possible risk factors and their association with HBsAg positivity at Dessie Referral
Hospital ANC, Northeast Ethiopia, 2014
Variable HBsAg Status
COR (95% CI)
P –
Value AOR (95% CI)
P –
ValuePositive
n (%)
Negative
n (%)
Age 18 -30 11 (4.4) 238 (95.6) 1 - -
31 – 42 8 (5.9) 128 (94.1) 1.35  (0.5 – 3.44 0.527 - -
Residence Urban 18 (5.6) 304 (94.4) 1
Rural 1(1.6) 62 (98.4) 0.23 (0.03 – 2.08) 0.210 - -
Marital Status Single 3 (18.8) 13 (81.2) 1 - -
Married 13 (3.7) 340 (96.3) 0.2 (0.4 – 0.6) 0.010 - -
Widowed 2 (22.2) 7 (77.8) 1.2 (0.2 – 9.3) 0.835 - -
Divorced 1 (14.3) 6 (85.7) 0.72 (0.06 – 8.5) 0.796 - -
Educational Status
No Formal Education 13 (25) 39 (75) 27.7  (7.5 – 101) 0.000 31.6 (4.5 – 225) 0.001
Primary school 3 (3.7) 78 (96.3) 3.2 (0.6 – 16) 0.160 0.9 (0.1 – 6.9) 0.915
Secondary School &
Above
3 (1.2) 249 (98.8) 1 1
Occupation Employed 6 (4.4) 129 (95.6) 1.4  (0.2 – 12.4) 0.739 - -
Housewife 7 (3.5) 19 (96.5) 1.12 (0.13 – 9.4) 0.918 - -
Daily Laborers 5 (29.4) 12 (70.6) 12.9 (1.3 – 122) 0.026 - -
Others 1 (3.1) 31 (96.9) 1
Ear piercing Yes 19 (6.6) 268 (93.4) - - - -
No 0 98 (100)
Nose piercing Yes 8 (24.2) 25 (75.8) 9.9 (3.6 – 26.9) 0.000 18.1 (2.9 – 114) 0.002
No 11 (3.1) 341 (96.9) 1 1
History of multiple
sexual practices Yes 15 (16.5) 76 (83.5) 14.3 (4.6 –44.4) 0.000 13.5 (2.3 – 78) 0.004
No 4 (1.4) 290 (98.6) 1 1
History of surgical
procedure Yes 0 12 (100)
- - - -
No 19 (5.1) 354 (94.9)
History of blood
transfusion Yes 0 4 (100)
- - - -
No 19 (5) 362 (95)
Gravidity Primigravida 1 (0.7) 143 (99.3) 1 1
Multigravidae 18 (7.5) 223 (92.5) 11.5 (1.5– 87) 0.018 1.65 (0.14– 19.2) 0.690
Parity Nullipara 9 (5.1) 169 (94.9) 1
Multipara 10 (4.8) 197(95.2) 1.76  (0.45 – 6.9) 0.415 - -
History of abortion Yes 13(23.6) 42 (76.4) 16.7 (6 –46) 0.000 9.1 (1.9 – 44) 0.005
No 6 (1.8) 324 (98.2) 1 1
Home delivery Yes 7 (17.1) 34 (82.9) 5.7 (2.1 – 15.4) 0.001 1.2 (0.24– 6.2) 0.807
No 12 (3.5) 332 (96.5) 1 1
HIV status Positive 12(22.6) 41 ((77.4) 13.6 (5.1 –36.5) 0.000 0.6  (0.12 – 3.68) 0.600
Negative 7 (2.1) 325 (97.9) 1 1
COR – Crude odds ratio, AOR – Adjusted odds ratio, CI – Confidence interval
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Only three pregnant women were positive for anti-HCV antibody. Due to these small number of
HCV positive women, the different categories of the variables do have zero cell values.
Therefore, it was impossible to conduct logistic regression analysis. However, all of the three
HCV sero-positive pregnant women had history of exposure to risk factors like ear piercing,
history of multiple sexual partners, history of abortion, history of home delivery by traditional
birth attendants and HIV positive (Table 3).
Table 3: Possible risk factors and their association with ant-HCV antibody positivity at Dessie
Referral Hospital ANC, Northeast Ethiopia, 2014
Variable Total
n (%)
HCV anti-body status
Positive
n (%)
Negative
n (%)
Ear piercing Yes 287 (74.5) 3 (1) 284 (99)
No 98 (25.5) 0 98 (100)
Nose piercing Yes 33 (8.6) 1 (3) 32 (97)
No 352 (91.4) 2 (0.6) 350 (99.4)
History of multiple sexual practices Yes 91 (23.6) 3 (3.3) 88 (96.7)
No 294 (76.4) 0 294 (100)
History of surgical procedure Yes 12 (3.1) 0 12 (100)
No 373 (96.9) 3 (0.8) 370 (99.2)
History of blood transfusion Yes 4 (1) 0 4 (100)
No 381 (99) 3 (0.8) 378 (99.2)
Gravidity Primigravida 144 (37.4) 0 344 (100)
Multigravida 341 (62.6) 3 (1.2) 238 (98.8)
History of abortion Yes 55 (14.3) 3 (5.5) 52 (94.5
No 330 (85.7) 0 330 ((100)
Parity Nullipara 178 (46.2) 0 178 (100)
Multipara 207 (53.8) 3  (1.4) 204 (98.6)
Home delivery Yes 41 (10.6) 3 (7.3) 38 (92.7)
No 344 (89.4) 0 344 (100)
HIV status Positive 53 (13.8) 3 (5.7) 50 (94.3)
Negative 332 (86.2) 0 332 (100)
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5. Discussion
Hepatitis B and Hepatitis C viruses are among the most prevalent infectious agents that causes
liver disease in humans worldwide (2, 7). Hepatitis B virus and HCV infections affecting
pregnant women may result in severe disease to the mother and chronic infection to the newborn
(5, 6). In this study, the overall sero-prevalence of HBsAg and anti- HCV antibody were 4.9%
and 0.8% respectively.
The prevalence of HBsAg among pregnant women found in Dessie was nearly similar to the
report from Debre-Tabor town which was 5.3% (28). By another study, a 3.7% prevalence of
HBV infection among pregnant women was previously reported in the southwestern part of
Ethiopia, Jimma (26). Different reports showed different prevalence of HBV infection among
pregnant women in different parts of the world. The prevalence of HBV infection among
pregnant women was reported 5.6% in Sudan (46), 4.1% in Saudi Arabia (35) and 4.6% in
Pakistan (32). On the other hand, lower prevalence of HBV infection was reported in India
(0.9%) (29), Iran (0.7%) (33) and Egypt (1.75%) (45). The lower prevalence in these previous
studies might be due to differences in diagnostic methods in which the test method were ELISA
but rapid test kits were used in the present study. However, higher prevalence of HBsAg were
reported in Gondar town, Ethiopia 7.3% (27), Yemen 10.8% (34), Cameroon 7.7% (37), Mali
8.0% (38) and Nigeria 9.3% (40). These discrepancies in the prevalence of HBsAg might be
due to the difference in sample size, awareness of the routes of HBV transmission, the
differences in demographic characteristics of the study population such as traditional practices
and sexual practices.
The prevalence of HBV and HCV infections found in the current study can be graded as
intermediate and low prevalence respectively according to WHO criteria (47, 48). The
prevalence of HBV infection can be divided into three main categories namely: high when
the prevalence is > 8%, intermediate when the prevalence is between 2-8% and low when <
2% (47). Hepatitis C virus infection can be graded high, moderate or low when the
prevalence is > 3.5%, 1.5% - 3.5% and < 1.5% respectively (48).
In this study the prevalence of anti-HCV antibody was 0.8%. This finding is in line with previous
reports among pregnant women in Sudan (0.6%) (46) and Benin City, Nigeria (0.8%) (43).
Relatively similar HCV prevalence was observed in India (1.03%) (30), Iran (0.2%) (33) and
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Abuja, Nigeria (0.5%) (42). In contrast, higher prevalence of anti-HCV antibody was reported
from Italy (2.4%) (31), Pakistan (7.0%) (32), Yemen (8.5%) (34), Burkina Faso (2.14) (36),
Egypt (8.6%) (45) and Gondar, Ethiopia (1.3%) (27). This disparity of the sero-prevalence of
HCV might be due to the differences in diagnostic methods, the difference in sample size, the
difference in hepatitis epidemiology in these countries, awareness about risk factors, socio-
cultural and behavioral differences.
Even though the difference was not statistically significant, in the present study the prevalence of
HBsAg was higher in the age group greater than 30 years old (5.9%) as compared to younger age
group women ( ≤ 30 years old) (4.4%). This finding is in agreement with the results which were
reported in previous studies conducted in Iran (33) and Saudi Arabia (35). Similarly, in a study
conducted in Jimma, Ethiopia the age group between 30 – 34 years and greater than 40 years old
had higher prevalence of HBV infection (26). On the contrary, other studies conducted in Debre-
Tabor town of Ethiopia (28) and Kano state of Nigeria (41) reported higher HBsAg prevalence
among the age group less than 30 years old. This discrepancy might be due to variation in the
number of study population in each age group.
Regarding anti-HCV antibody positivity, all positive pregnant women were in the age group less
than 30 years old.  This finding is in line with similar study conducted in India in which majority
of anti-HCV antibody positive cases was observed in the age group less than 30 years old (30).
In a study conducted in Benin city of Nigeria a dominant proportion of HCV prevalence was
observed among the age group less than 32 years old (43).
In the current study, with the exception of educational status, all the other socio-demographic
variables didn’t show significant association with HBV infection among pregnant women.
Similar associations of demographic factors were also reported in Cameroon (37). In the present
study, prevalence of HBV infection was found inversely associated with increased educational
status. Pregnant women who had no formal education had a higher risk of infection than
pregnant women with educational level of secondary school and above. This finding is in line
with studies conducted in Nigeria among the same study population (39, 40). This higher
prevalence of HBV among pregnant women who had no formal education might be due to the
lack of awareness about the route of transmission and methods of prevention.
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History of nose piercing, history of multiple sexual partners and history of abortion were found
to be significant predictors of HBV sero-prevalence among pregnant women in the present study.
There was also other report that documented similar findings in Kano state of Nigeria (41). In
addition, history of abortion was significantly associated with HBV infection in a study
conducted in Jimma town (26). In the present study, having history of abortion increased the risk
of having HBV infection more than nine times as compared with those who had not suffered
such experience. On the other hand, though multivariate logistic analysis showed no significant
association, bivariate logistic regression analysis indicated that history of home delivery by
traditional birth attendants, multigravida and HIV infection were found significant predictors of
HBV infection in the present study.
In this study history of blood transfusion and surgical procedures were not associated with the
sero-prevalence of HBV. In contrast to this finding, history of surgical procedures and history of
blood transfusion have been significantly associated with sero-prevalence of HBV prevalence in
studies conducted in Pakistan (32), Kano State of Nigeria (41) and Egypt (45). In the present
study, we noticed that the number of pregnant women that had history of blood transfusion or
history of previous surgery was small which might contributed for the absence of these variables
association with HBV infection among pregnant women. Transfusion-transmissible infectious
agents such as HBV, HCV, HIV and syphilis are among the greatest threats to blood safety for
transfusion recipients and pose a serious public health problem (49).
Higher prevalence of anti-HCV antibody were observed among study subjects who had history
of ear piercing, history of having multiple sexual partner, multi-gravida, history of abortion,
multi-parity and home delivery by traditional birth attendants. This finding is in agreement with
studies reported from Sudan (46) and Benin City of Nigeria (43). Previous surgical procedure,
history of frequent injections and ear piercing were reported as risk factors for HCV infection in
a study conducted in Egypt (50).
The current study revealed that there was no significant association between sero-prevalence of
HBsAg and HIV status of the women in multivariate logistic regression analysis (P > 0.05). The
reason for this might be due to the presence of small number of HIV positive pregnant women as
compared to HIV negative pregnant women. A similar picture was observed in previous studies
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conducted in Mali (38) and Benin City of Nigeria (43) in which HIV status of pregnant women
did not significantly affect the prevalence of HBV infection.
In the present study, there was no HBV and HCV co-infection. This is supported by a study
conducted previously among blood donors in Amhara and Tigray national states where there was
no HBV and HCV co-infection (22).
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6. Limitation of the Study
 Only HBsAg were used for the detection of HBV infection. Other sero-markers were not
included due to budget constraints.
 Only rapid test kits were used for the detection of HBsAg and anti-HCV antibody. Usually
confirmatory test is commonly used to evaluate positive rapid test results. Due to resource
constraints this study was unable to conduct confirmatory tests for those positive results.
 Since this study was hospital based study, it may not reflect the true prevalence among
the general population in the area.
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7. Conclusion and Recommendation
7.1. Conclusion
This study has found that the sero-prevalence of HBsAg and ant-HCV antibody among pregnant
women was 4.9% and 0.8% respectively. Results from this study have shown that HBV
prevalence in pregnant women is of intermediate prevalence and multiple sexual practice, nose
piercing and history of abortion were associated with HBV infection in the area.
The study also showed a low prevalence of HCV infection in the area. Majority of anti-HCV
antibody positive pregnant women had history of exposure to risk factors like ear piercing,
history of multiple sexual partners, history of abortion, history of home delivery by traditional
birth attendants and HIV positive
7.2. Recommendation
 Free screening of all pregnant women for HBV and HCV should be made as part of
routine antenatal care service.
 Awareness creation should be made for pregnant women on risk factors such as multiple
sexual practice and nose piercing for the transmission of HBV.
 Further study on HBsAg and anti-HCV antibody positive pregnant women should be
conducted to determine HBeAg and HCV – RNA positivity which is important to know
the extent of vertical transmission in the area.
 Further population based study should be conducted to know the exact prevalence of
HBV among the general population in the area.
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Annex I: English Version Information Sheet
University of Gondar
College of Medicine and Health Sciences
School of Biomedical and Laboratory Science
Study Title: Sero-prevalence and associated risk factors of HCV and HBV infections among
pregnant women attending ANC at Dessie Referral Hospital; Northeast Ethiopia.
Purpose
I planned to conduct a study with objective of investigating the magnitude of HBV and HCV
infection in pregnant women. The knowledge gained from this work is believed to help the
management and control of these viruses.
Participation
I am asking you and others to voluntarily participate in this study. What is expected from
everyone is to be examined for HBV and HCV and be asked to answer few questions in relation
to risk factors. The laboratory examination involves collection of 5 ml venous blood. All samples
are collected using sterile and disposable equipments: tubes, syringes and needles.
Risks and Discomforts Associated
Taking 5ml of blood doesn’t have any harm to your health except minor needle brick injury pain
which lasts only for micro second. However if you have any discomfort you will be seen by
physician.
Benefits
If there is any positive finding in laboratory investigation the result will be communicated to
your physician and prescription of treatment and advice will be effected.
Confidentiality
Any information that I collect about you during this research will be kept confidential.
32
Information about your identity will be put away after recording your file; and kept in a secured
place. Only the principal investigator will be able to link your identity with the code number.
Sharing the Result
At the end of this study I will write a report about the results of the study through publication or
any other means. The reports won’t bear any information relevant to your personality e.g. your
name or identity. I assure you the confidentiality of such information. Thus I also need your
permission to use the test results for writing a report.
Right to Refuse
Since participation in this study is entirely voluntary. You can refuse to participate in this
research at any time. Your refusal to participate in this study will not affect any of the benefits
you are supposed to get from the clinic.
Contact Address
If you have any further question and in case of urgency you can contact the principal investigator
at any time using the following address:-
Name:- Mohammed Seid (Principal investigator)
Address: - University of Gondar College of Medicine and Health Sciences School of Biomedical
and Laboratory Science
City:- Gondar
Telephone (mobile):- +251920272420
Email:- mohammed.seid@yahoo.com
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Annex II: English Version Consent Form
I, the undersigned, confirm that, as I give consent to participate in the study, it is with a clear
understanding of the objectives and conditions of the study and with recognition of my right to
withdraw from the study if I change my mind.
I……………………………do her by give consent to ……………………. to include me in this
study. I have been given the necessary information about the study. I have also been assured that
I can withdraw my consent at any time without penalty or loss of benefits. The proposal has been
explained to me in the language I understand.
Name of the study participant: ______________________________
Participant’s Signature: _________________
Name and role of the person obtaining consent: _______________________________
Signature of person obtaining consent: ________________________
Date: ________________________
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Annex III: Amharic Version Information Sheet
የጎንደር ዩኒቨርስቲ
የህክምናና ጤና ሣይንስ ኮሌጅ
የባዮሜድካልና ላቦራቶሪ ሣይንስ ትምህርት ቤት
KØ“~ S[Í“ }dታፊነት መግለጫ ቅጽ
¾Ø“~ `°e: ሄፓታይተስ ቢ እና ሲ ¾}vK< Ñ<uƒ ›UÜ ቫይረሶች uነፍሰ Ö<` እ“„‹
Sካከል ያላቸዉ ስርጭትና አጋላጪ ሁኔታዎች፡፡
የጥናቱ ዓላማ
የሄፓታይተስ ቢ እና ሲ ቫይረሶች uነፍሰ Ö<` እ“„‹ መካከል ያለዉን ስርጭት ለማጥናት
የታቀደ ነዉ፡፡
በጥናቱ ስለመሳተፍ
በዚህ ጥናት መሳተፍ በሙሉ ፈቃደኝነት ላይ የተመሰረተ ነዉ፡፡ ስለሆነም በጥናቱ እንዲሳተፉ
ፈቃደኛነትዎን እንጠይቃለን ፡፡ ለመሳተፍ ከፈቀዱ 5 ሚሊ ሊትር የደም ናሙና ከክንድዎ
ተወስዶ የላቦራቶሪ ምርመራ ይደረግሎታል ፡፡ የላቦራቶሪ ምርመራውም ሄፓታይተስ “ቢ” እና
“ሲ” ቫይረስን በደሞ ዉስጥ መኖር ና አለመኖር ማረጋገጥ ይሆናል ፡፡ የደም ናሙናዉም
የሚወሰደዉ ንጽህናዉ በተጠበቀ አዲስ እና በታሸገ መርፌ ና ስሪንጅ ነዉ፡፡
በጥናቱ ሊከሰቱ የሚችሉ ተያያዥ ችግሮች
›Ueƒ ሚሊ ሊትር የደም ናሙናዉን ለመዉሰድ መርፌ ሲገባ ከሚፈጥረዉ የቅጽበት
የህመም ስሜት በስተቀር የጎላ ችግር አያመጣም ነገር ግን ምቾት ካልተሰማዎት ሀኪም
እንዲያይዎት ይደረጋል ፡፡
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በጥናቱ በመሳተፍ የሚገኝ ጥቅም
የደም ናሙና የላብራቶሪ ዉጤት ምንም አይነት ችግር ካሳየ የመድሃኒት ትእዛዝ ና የባለሙያ
ምክር ይሰጥዎታል፡፡
የጥናቱ መረጃዎች ሚስጥራዊነት
በጥናቱ ውስጥ የተሰበሰቡ ማናቸዉም ግላዊ መረጃዎች ሚስጥራዊነታቸዉ የተጠበቀ ይሆናል፡፡
ከማንነትዎ ጋር በቀጥታ ተያያዥነት ያላቸዉ መረጃዎች በሙሉ በዋና ተመራማሪዉ
ሚስጥራዊ በሆነ የመረጃ ጥንቅር ዘዴ ከተቀየሩ በኃላ ብቻ ለምርምር ሂደቱ የሚዉሉ
ይሆናሉ፡፡
የጥናቱን ዉጤት ስለማሳወቅ
የዚህ ጥናት ዉጤት በተለያዩ የህትመት ውጤቶች የሚቀርብ ሲሆን ይህ ከማንነትዎ ጋር
የተያያዘ ምንም አይነት መረጃን አያካትትም፡፡ ስለዚህም የጥናቱን ዉጤት በሪፖርት እናቀር
በዉ ዘንድ ፈቃድዎን እንጠይቃለን፡፡
ከጥናቱ ስለ መዉጣትና ስለማቋረጥ
ይህ ጥናት በፈቀደኝነት ላይ የተመሰረተ እንደመሆኑ መጠን በማንኛዉም ወቅት በፈቃድዎ
ከጥናቱ መዉጣት ይችላሉ፡፡ ከጥናቱ ቢወጡም እንኳን የተለመደዉን የህክምና እርዳታ በጤና
ተቋሙ ዉስጥ በማንኛዉም ጊዜ የማግኘት መብት አልዎት፡፡
ከጥናቱ ጋር በተያያዘ ማናቸውም ጥያቄ ቢኖርዎ በሚከተለዉ አድራሻ ጥያቄዎን ማቅረብ
ይችላሉ፡-
ዋና ተመራማሪ፡- መሀመድ ሠይድ
አድራሻ፡- የጎንደር ዩኒቨርስቲ የህክምናና ጤና ሣይንስ ኮሌጅ የባዮሜድካልና ላቦራቶሪ ሣይንስ
ትምህርት ቤት
ሞባይል ስልክ፡- 251920272420
ኢሜል፡- mohammed.seid@yahoo.com
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Annex IV: Amharic Version Consent Form
ስለ ስምምነቱ ማረጋገጫ ፊርማ
እኔ ስሜ ከታች የተገለፀዉ የጥናቱ ተሳታፊ ለመሆን ስወስን የጥናቱን አላማዎች አሰራሮችና
ቅድመ ሁኔታዎች በግልጽ በመረዳትና ከጥናቱ ተሳታፊነት ፈቃደኛነቴን በማንኛዉም ደረጃ
የማንሳት መብቴን በማረጋጥ ነዉ፡፡
እኔ ------------------------------------- በጥናቱ ተሳታፊ መሆኔን በፊርማዬ እያረጋገጥሁ ይህንን
ስወስን በጥናቱ ሳቢያ ሊከሰቱ የሚችሉ አደጋዎች በሚገባ የተረዳሁ ና ከጥናቱ በማንኛዉም
ደረጃ እራሴን ለመሰረዝ ብወስን ተገቢ የሆኑ ህክምናዎች ና እገዛዎች ሁሉ እነደማይነፍጉኝ
በማመን ነዉ፡፡ እነዚህ መረጃዎች ሁሉ በሚገባ በምረዳዉ ቋንቋ የተገለጸልኝ መሆኑን በፊርማዬ
አረጋግጣለሁ ፡፡
የጥናቱ ተሣታፊ ሙሉ ስም፡ --------------------------------------------------------
ፊርማ፡ ---------------------
የተመራማሪዉ ሙሉ ስም፤ --------------------------------------------------------
ፊርማ፡ --------------------------
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Annex V: English Version Questionnaire
University of Gondar
College of Medicine and Health Sciences
School of Biomedical and Laboratory Science
Questionnaire to assess socio-demographic characteristics and Risk factors
For data collectors: Please write on the space provided or circle on the answer among choices
accordingly.
Code : _____________ Date: _____________
Section One: Background of the study participants
1 How old are you? [ ______] age in years
2 Current residence? 1. Urban
2. Rural
3 Marital Status 1. Single
2. Married
3. Widowed
4. Divorced
4 Educational Status 1. No formal education
2. Primary school (1 – 8)
3. High school and Above
5 Occupation 1. Government employed
2. Private employed
3. Housewife
4. Daily laborer
5. Merchant
6. Farmer
7. Others (Specify) ________
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Section Two: Possible risk factors
6 Ear piercing? 1. Yes
2. No
7 Nose piercing? 1. Yes
2. No
8 History of multiple sexual practices? 1. Yes
2. No
9 History of surgical procedure? 1. Yes
2. No
10 History of blood transfusion? 1. Yes
2. No
11 How many pregnancies do you have
including this one?
1. First time
2. Second time
3. Three and above (Specify
in numbers) ___________
12 Do you have abortion /stillbirth/
history?
1. Yes
2. No
13 How many deliveries do you have
previously?
1. No previous delivery
2. One
3. Two and above (Specify in
numbers) ___________
14 Home delivery by traditional birth
attendants?
1. Yes
2. No
15 HIV status 1. Positive
2. Negative
3. Unknown
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Annex VI: Amharic Version Questionnaire
የጎንደር ዩኒቨርስቲ
የህክምናና ጤና ሣይንስ ኮሌጅ
የባዮሜድካልና ላቦራቶሪ ሣይንስ ትምህርት ቤት
ማህበራዊ ነክ መረጃዎችንና አጋላጭ የሆኑ ሁኔታዎችን ለመዳሰስ የተዘጋጀ መጠይቅ
ለመረጃ ሰብሳቢዎች፤ ጥያቄዉን ከጠየቃችሁ በኃላ መልሱን በተሰጠዉ ክፍት ቦታ ወይም
ከተሰጡት አማራጮች አንዱን በማክበብ ይጻፉ፡፡
ኮድ : _____________ ቀን: _____________
ክፍል 1፡ አጠቃላይ ማህበራዊ ነክ መረጃዎች
1 እድሜ [ ______] ዓመት
2 የመኖሪያ አካባቢ? 1. ከተማ
2. ገጠር
3 የጋብቻ ሁኔታ 1. ያላገባች
2. ያገባች
3. ባል የሞተባት
4. የፈታች
4 የትምህርት ደረጃ 1. መደበኛ ትምህርት
ያልተማረች
2. የመጀመሪያ ደረጃ ት/ት (1
– 8)
3. የሁለተኛ ደረጃ ት/ትና ከዚያ
በላይ
5 የሥራ ሁኔታ 1. የመንግስት ተቀጣሪ
2. የግል ድርጅት ተቀጣሪ
3. የቤት እመቤት
4. የቀን ሰራተኛ
5. ነጋዴ
6. ገበሬ
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7. ሌላ (ይጠቀስ) _____
ክፍል 2፡ ለሄፓታይትስ ቢ ና ሲ አጋላጭ የሆኑ ሁኔታዎችን የሚዳስሱ ጥያቄዎች
6 ጆሮዎን ተበስተዉ ያዉቃሉ? 1. አዎ
2. አይደለም
7 አፍንጫዎን ተበስተዉ ያዉቃሉ? 1. አዎ
2. አይደለም
8 ከአንድ በላይ የፍቅር ጉደኛ ነበረዎት?
(ከአንድ ሠዉ በላይ የግብረስጋ ግንኙነት
ነበረዎት?)
1. አዎ
2. አይደለም
9 ማንኛዉንም አይነት ቀዶ ጥገና አሰርተዉ
ያዉቃሉ?
1. አዎ
2. አይደለም
10 ደም ከሌላ ሠዉ ተሰጥቶዎት ያዉቃል? 1. አዎ
2. አይደለም
11 የአሁኑን ጨምሮ ለስንተኛ ጊዜ አርግዘዋል? 1. ለመጀመሪያ ጊዜ
2. ለሁለተኛ ጊዜ
3. ለሦስትና ከዚያ በላይ
(በቁጥር ይጠቀስ) _____
12 አስዎርዶዎት ያዉቃል? 1. አዎ
2. አይደለም
13 ምን ያህል ልጆች ወልደሻል? 1. ወልጄ አላዉቅም
2. አንድ
3. ሁለትና ከዚያ በላይ
(በቁጥር ይጠቀስ) ____
14 በቤት ዉስጥ በልምድ አዋላጅ ተዋልደዉ
ያዉቃሉ?
1. አዎ
2. አይደለም
15 የ “ኤች አይ ቪ” ቫይረስ በደመዎ ዉስጥ
አለ? (የሴትዋን ካርድ በማየት የሚሞላ)
1. አዎ (ፖዜቲቭ )
2. አይደለም (ኔጋቲቭ )
3. አይታወቅም
41
Annex VII: Laboratory Procedures and Data Collection Format
Serological Test Principle and Procedure for HBsAg
EUGENE HBsAg
The EUGENE HBsAg rapid test (Shanghai Eugene Biotech co., Ltd) is a lateral flow
immunochromatorgraphic assay for the qualitative determination of HBsAg (a marker of HBV
infection) in human serum or plasma.
Test Principle
The EUGENE HBsAg rapid test a rapid qualitative immunochromatorgraphic assay employing
a unique combination of monoclonal dye-conjugate (colloidal gold) and polyclonal solid phase
antibodies to selectively identify HBsAg of HBV infection with a high degree of sensitivity. In
this test, plasma or serum specimen is added directly to the sample pad.  As the test sample flows
through the sample pad, the labeled antibody-dye conjugate binds to HBsAg forming an
antibody-antigen complex. The pad is in contact with a chromatographic test strip which contains
a region of immobilized polyclonal anti-HBsAg antibody in the test line. The antibody-antigen
complex moves by capillary action along the strip forming a line of immobilized complex by the
zone of antibody in the test line, indicating the presence of HBsAg in the sample (pink line). If
no antigen is present, the test line will remain clear. The appearance of a pink line in the control
line shows that the test has been carried out correctly.
Test Procedure
1. Bring the complete kit and sample to be tested to room temperature (15 – 30OC) prior to
testing.
2. Remove the test device from its protective pouch, lay it on a dry and clean flat surface,
and label the device with patient or control number.
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3. Use the dropper or pipette to withdraw serum specimen from the specimen collection
container and dispense 2 – 3 drops (approximately 80 - 120l) in to the sample well and
start the timer.
4. Wait for colored bands to appear. For strong positive, results may be observed within one
minute. For 5ng/ml, read within 5 – 10 minutes; for 1.5 – 2ng/ml read within 15 – 20
minutes. However, to confirm negative results, the complete reaction time 20 – 30
minutes is required. Do not interpret result after 30 minutes.
Interpretation of Results
Negative: One pink line appears in control line, showing the test has been carried out correctly.
There will be no line in test region.
Positive: In addition to a pink colored control line, a distinct pink colored band will also appear
in the test region. Any shade of color in the test region (T) should be considered positive.
Invalid: A total absence of color in both regions is an indication of procedure error and/or that
the test reagent has deteriorated. Repeat the testing using a new device.
Serological Test Principle and Procedure for Anti-HCV Rapid Test
The EUGENE Anti-HCV rapid test (Shanghai Eugene Biotech co., Ltd) is a sandwich lateral
flow immunochromatorgraphic assay for the qualitative detection of antibodies to HCV in
human serum or plasma.
Test Principle
The EUGENE Anti-HCV rapid test is a lateral flow immunochromatorgraphic assay screening
serum or plasma using recombinant HCV proteins. Recombinant antigens of HCV labeled by
gold conjugates are used in test band as capture materials, and anti-rabbit HCV antibody is used
in the control band. When a sample is added in to the sample well of the device, it migrates
through the membrane strip. If the antibodies to HCV present in the specimen, a complex of
antibody- gold conjugated recombinant antigens will be formed, which is then captured by
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antigen immobilized in the test zone of the membrane, producing a visible pink color band of
immunocomplex conjugate on the membrane. The color intensity will depend on the
concentration of the ant-HCV present in the sample. Absence of the test band suggests a negative
result. The test contains an internal control (C band) which should exhibit a pink colored band of
the immunocomplex conjugate regardless of color development on the test band. Otherwise, the
test result is invalid and the specimen must be retested with another device.
Test Procedure
1. Bring the complete kit and sample to be tested to room temperature (15 – 30OC) prior to
testing.
2. Remove the test device from its protective pouch, lay it on a dry and clean flat surface,
and label the device with patient or control number.
3. Hold the dropper vertically and transfer only one drop (about 25l) of serum or plasma to
the specimen well (S) of the test device, then add two drops (about 100l) of buffer and
start the timer.
4. Wait for the red line (s) to appear. The result should be read at 10 – 20 minutes. Do not
interpret result after 20 minutes.
Interpretation of Results
Negative: If only the C band is developed, the test indicates that no detectable antibodies to
HCV present in the specimen. The result is negative.
Positive: If both C and T bands are developed, the test indicates for the presence of antibodies to
HCV in the specimen. The result is positive. Any shade of color in the test region (T) should be
considered positive.
Invalid: If no C band is developed, the assay is in valid regardless of color development on the T
band. Repeat the assay using a new device.
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Serological Test Principle and Procedure for HIV - 1 and HIV – 2
HIV 1/2 STAT-PAK™ (Chembio Diagnostics)
The Chembio HIV 1/2 STAT-PAK™ Assay (CHEMBIO DIAGNOSTIC SYSTEMS, INC.,
MEDFORD, NY, USA) is a single-use immunochromatographic test for the detection of
antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma specimens. The Chembio HIV
1/2 STAT-PAK™ assay is intended for use as a point of- care test to aid in the diagnosis of
infection with HIV-1 and HIV-2. This test is suitable for use in multi-test algorithms designed
for the statistical validation of rapid HIV test results.
Test Principle
The Chembio HIV 1/2 STAT-PAK™ Assay employs a unique combination of a specific
antibody binding protein which is conjugated to colloidal gold dye particles and HIV-1/2
antigens which are bound to the solid phase membrane. Whole blood, serum or plasma is applied
to the SAMPLE (S) well of test device followed by the addition of running buffer. The buffer
facilitates the lateral flow of the specimen and test reagents and promotes the binding of the
antibodies to the antigen. The specimen/buffer mixture migrates along the test strip by capillary
action, reconstituting the conjugate. If present, the antibodies bind to the colloidal gold
conjugated antibody binding protein. In a reactive sample, the dye conjugated-immune complex
migrates on the nitrocellulose membrane and is captured by the antigens immobilized in the
TEST (T) area producing a pink/purple line. In the absence of HIV-1 and HIV-2 antibodies,
there is no pink/purple line in the TEST (T) area. The sample continues to migrate along the
membrane and produces a pink/purple line in the CONTROL (C) area containing
immunoglobulin G antigens. This procedural control serves to demonstrate that specimen and
reagents have been properly applied and have migrated through the device.
Test Procedure
If the specimen to be tested is refrigerated, remove it from the refrigerator and allow it to come
to a temperature of 18 to 30°C: (64 to 86°F) prior to testing.
1. Remove the Chembio HIV 1/2 STAT-PAK™ test device from its pouch and place it on a flat
surface.
2. Label the test device with patient name or identification number.
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3. Touch the 5 l sample loop provided to the specimen, allowing the opening of the loop to fill
with the liquid.
4. Holding the sample loop vertically, touch it to the sample pad in the center of the SAMPLE
(S) well of the device to dispense ~5 μL of sample (serum, plasma or whole blood) onto the
sample pad.
5. Invert the Running Buffer bottle and hold it vertically (not at an angle) over the sample well.
Add 3 drops (~ 105 μL) of buffer slowly, drop-wise, into the SAMPLE (S) well.
6. Read the test result between 15 and 20 minutes after the addition of the running buffer.
Reactive test results may be observed and read earlier than 15 minutes. To verify a non-
reactive test result, wait the entire 15 minutes after starting the test. Do not read results after
20 minutes.
Interpretation of Test Results
NON-REACTIVE: One pink/purple line in the control (C) area, with no line in the test (T) area
indicates a non-reactive Test Result. A non-reactive test result means that HIV-1 and HIV-2
antibodies were not detected in the specimen. The test result is interpreted as negative for HIV-1
and HIV-2 antibodies. However, this does not exclude possible infection with HIV.
REACTIVE: Two pink/purple lines, one in the test (T) area and one in the control (C) area
indicate a reactive test result. The line in the test (T) area may look different from the line in the
control (C) area. Intensities of the Test and Control Lines may vary. Test result with visible lines
in both test (T) and control (C) areas, regardless of intensity, is considered reactive. A reactive
test result means that HIV-1 and/or HIV-2 antibodies have been detected in the specimen. The
Test Result is interpreted as Preliminary positive for HIV-1 and/or HIV-2 antibodies.
INVALID: A pink/purple line should always appear in the control (C) area, whether or not a line
appears in the test (T) area. If there is no distinct pink/purple line visible in the control (C) area,
then the test is invalid. Any lines that appear outside of the control (C) area or test (T) area is an
invalid test. An invalid test cannot be interpreted. It is recommended that the Invalid test be
repeated with a new device.
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KHB Rapid test
The rapid test for HIV 1/2 (KHB Shanghai Kehua Bio-engineering Co. Ltd, China)is an in-vitro,
visually read test for the qualitative determination of antibodies to HIV – 1 and HIV – 2 in
human serum, plasma or whole blood. The test is intended to be used as an aid to detect
antibodies to HIV 1/2 from infected individuals.
Test Principle
The rapid test of HIV 1/2 from KHB adopts the solid phase colloidal gold
immunochromatographic technology for the qualitative detection of antibodies to HIV 1/2. The
gold – gp160 conjugate and the gold – gp36 conjugate are coated to the conjugate pad in
advance. The test line (HIV type I + II antigens) and the control line (monoclonal antibody
against gp160) are pre-coated on the surface of the NC membrane. When the sample that added
to the sample pad migrates through the conjugate pad, it reconstitutes and mixes with the
colloidal gold - antigen conjugates.  The mixture continues to migrate through the NC membrane
to the pre-coated antigens or antibody that present on the membrane. A reddish - purple test line
will be visible in the strip if there are enough antibodies to HIV 1/2 in the sample.  If antibodies
to HIV 1/2 are absent, or are present at very low level, then no color will appear in the test line.
The control line of reddish – purple is for quality control only and thus does not affect the test
result.
Test procedure
1. Remove the KHB device from its packaging, and label it using a code number or a client
identification number. Place in a flat surface.
2. Add about 40l of sample to the sample area and then add one drop of sample diluents  to the
same area.
3. Read the test result between 15 -30 minutes after the addition of the running buffer. Reactive
test results may be observed within 2 - 3 minutes. To verify a non-reactive test result, wait
the entire 30 minutes after starting the test.
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Interpretation of Test Results
Negative: One pink-purple line in the control (C) area, with no line in the test (T) area indicates
a non-reactive test result.
Positive: Two pink-purple lines, one in the test (T) area and one in the control (C) area indicate a
reactive test result. The line in the test (T) area may look different from the line in the control (C)
area. Intensities of the Test and Control lines may vary. Test result with visible lines in both test
(T) and control (C) areas, regardless of intensity, is considered reactive.
Invalid: If there is no distinct pink/purple line visible in the control (C) area, then the test is
invalid.
Uni-Gold HIV 1/2 Rapid Test Kit
Uni-Gold™ Recombigen® (Trinity Biotech Plc Bray, Co. Wicklow, Ireland) HIV-1/2 is a single
use rapid immunoassay, for the qualitative detection of antibodies to HIV-1 and/or HIV-2 in
serum, plasma and whole blood. Uni-Gold™ Recombigen® HIV-1/2 is intended for use in point
of care settings as an aid in diagnosis of infection with HIV-1 and/or HIV-2. This test is suitable
for use in appropriate multi-test algorithms designed for the statistical validation of rapid HIV
test results.
Test principle
Uni-Gold™ Recombigen® HIV-1/2 was designed as a rapid immunoassay and is intended to
detect antibodies to HIV-1 and/or HIV-2 in human serum, plasma and whole blood. Uni-Gold™
Recombigen® HIV-1/2 uses proteins representing regions of the HIV virus. If antibodies to
HIV-1 and/or HIV-2 are present in the sample, they combine with these proteins and a color
reagent and this complex binds to the proteins in the test forming a visible pink/red band in the
test region of the device adjacent to the word ‘Test’. The control line should always appear as a
visible pink/red band in the control region of the device to indicate that the test device is
functioning correctly. A reactive result is indicated by a pink/red band in the test region of the
device. A non-reactive result occurs in the absence of detectable levels of antibodies to HIV-1
and/or HIV-2 in the specimen; consequently no visually detectable band develops in the test
region of the device.
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Test Procedure
1. Allow the kit (unopened devices and wash solution) to reach room temperature (15 – 27°C if
previously stored in the refrigerator.
2. Remove the required number of Uni-Gold HIV-1/2 devices from their pouches and lay the
devices on a clean flat surface.
3. Label each device with the appropriate patient information / Identification number/.
4. Draw up adequate sample to the first gradation on the Pipette using one of the disposable
pipettes included in the kit. Use only the disposable pipette included in the kit and do not
reuse. If kit Controls are being run, these must be used as described in the package insert
provided with the kit controls.
5. Holding the Disposable Pipette vertically over the sample port, add one free falling drop of
sample carefully. Do not add the full volume contained within the disposable pipette allow
the sample to absorb into the paper in the sample port. Ensure air bubbles are not introduced
into the sample port. Discard the disposable pipette in a biohazard waste container.
6. Holding the dropper bottle of wash solution in a vertical position, add four drops of wash
solution to the sample port.
7. Set the timer for 10 minutes and start timing the test.
8. Read test results after 10 minutes but not more than 12 minutes incubation time.
Interpretation of Test Results
Reactive: A pink/red line of any intensity appears in the device window adjacent to word "Test"
and a second pink/red line of any intensity appears adjacent to word "Control". This indicates a
reactive result that is interpreted as preliminary positive for HIV-1 and/or HIV-2 antibodies.
Non-Reactive: A pink/red line of any intensity appears in the device window adjacent to word
"Control", but no pink/red line appears in the device window adjacent to "Test". This indicates a
Non-Reactive result that is interpreted as Negative for HIV-1 and/or HIV-2 antibodies.
Invalid: No pink/red line appears in the device window adjacent to word "Control" whether or
not a pink/red line appears in the device window adjacent to word "Test". This is an Invalid
result that cannot be interpreted. The test should be repeated in duplicate with fresh devices.
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Laboratory Data Collection Format
